PMID- 22231555
OWN - NLM
STAT- MEDLINE
DCOM- 20120709
LR  - 20211021
IS  - 2042-0226 (Electronic)
IS  - 1672-7681 (Print)
IS  - 1672-7681 (Linking)
VI  - 9
IP  - 2
DP  - 2012 Mar
TI  - Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 
      as a tumor-associated antigen against colorectal cancer.
PG  - 175-83
LID - 10.1038/cmi.2011.52 [doi]
AB  - Anterior gradient-2 (AGR2) promotes tumor growth, cell migration and cellular 
      transformation and its enhanced expression is almost completely restricted to 
      malignant tissues, thus making AGR2 an interesting target for the development of 
      immunotherapeutic strategies. We investigated whether the AGR2 molecule comprises 
      human leukocyte antigen (HLA)-A*0201-binding epitopes recognized by human 
      cytotoxic T lymphocytes (CTLs), which could be targeted in dendritic cell 
      (DC)-based cancer immunotherapy against colorectal cancer (CRC). We reviewed the 
      sequence of AGR2 for peptides that could potentially bind to HLA-A*0201 with the 
      aid of a computer-based program. Five candidate peptides with different binding 
      scores were synthesized and tested. These peptides were then assessed for their 
      immunogenicity to elicit specific immune responses mediated by CTLs in vitro by 
      means of enzyme-linked immunospot assays and CTL assays. AGR2 was highly 
      expressed in several CRC cell lines, including DK01, DLD1, KM12C, HCT-8 and 
      HT-29. DCs pulsed with AGR2-P2 (aa 11-19; LLVALSYTL) or AGR2-P4 (aa 127-135; 
      RIMFVDPSL) generated potent CTLs that could lyse T2 cells pulsed with AGR2-P2 or 
      AGR2-P4 and HLA-A0201(+) AGR2-positive CRC cell lines in a strong dose-dependent 
      and HLA-A*0201-restricted manner. In conclusion, these novel epitopes derived 
      from AGR2 protein may be attractive candidates for DC-based immunotherapy for 
      CRC.
FAU - Lee, Hyun Ju
AU  - Lee HJ
AD  - Research Center for Cancer Immunotherapy, Chonnam National University Hwasun 
      Hospital, Hwasun, Jeollanamdo, Korea.
FAU - Hong, Cheol Yi
AU  - Hong CY
FAU - Jin, Chun-Ji
AU  - Jin CJ
FAU - Kim, Mi-Hyun
AU  - Kim MH
FAU - Lee, Youn-Kyung
AU  - Lee YK
FAU - Nguyen-Pham, Thanh-Nhan
AU  - Nguyen-Pham TN
FAU - Lee, Hyunah
AU  - Lee H
FAU - Park, Byoung Chul
AU  - Park BC
FAU - Chung, Ik-Joo
AU  - Chung IJ
FAU - Kim, Hyeoung-Joon
AU  - Kim HJ
FAU - Lee, Je-Jung
AU  - Lee JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120109
PL  - China
TA  - Cell Mol Immunol
JT  - Cellular & molecular immunology
JID - 101242872
RN  - 0 (AGR2 protein, human)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (HLA-A*02:01 antigen)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Mucoproteins)
RN  - 0 (Oncogene Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Proteins)
SB  - IM
MH  - Antigen Presentation
MH  - Antigens, Neoplasm/genetics/*immunology
MH  - Cell Line, Tumor
MH  - Coculture Techniques
MH  - Colorectal Neoplasms/genetics/*immunology/pathology/*therapy
MH  - Computational Biology
MH  - Cytotoxicity, Immunologic
MH  - Dendritic Cells/immunology/transplantation
MH  - Enzyme-Linked Immunospot Assay
MH  - Epitope Mapping
MH  - Epitopes/genetics/immunology
MH  - HLA-A2 Antigen/*immunology
MH  - Humans
MH  - *Immunotherapy
MH  - Lymphocyte Activation
MH  - Mucoproteins
MH  - Oncogene Proteins
MH  - Peptide Fragments/genetics/immunology
MH  - Protein Binding
MH  - Proteins/genetics/*immunology
MH  - T-Lymphocytes, Cytotoxic/immunology/*metabolism/pathology
PMC - PMC4002806
EDAT- 2012/01/11 06:00
MHDA- 2012/07/10 06:00
PMCR- 2012/03/01
CRDT- 2012/01/11 06:00
PHST- 2012/01/11 06:00 [entrez]
PHST- 2012/01/11 06:00 [pubmed]
PHST- 2012/07/10 06:00 [medline]
PHST- 2012/03/01 00:00 [pmc-release]
AID - cmi201152 [pii]
AID - 10.1038/cmi.2011.52 [doi]
PST - ppublish
SO  - Cell Mol Immunol. 2012 Mar;9(2):175-83. doi: 10.1038/cmi.2011.52. Epub 2012 Jan 
      9.